270 related articles for article (PubMed ID: 37766278)
1. Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro.
Pelz L; Piagnani E; Marsall P; Wynserski N; Hein MD; Marichal-Gallardo P; Kupke SY; Reichl U
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766278
[TBL] [Abstract][Full Text] [Related]
2. Defective Interfering Particles with Broad-Acting Antiviral Activity for Dengue, Zika, Yellow Fever, Respiratory Syncytial and SARS-CoV-2 Virus Infection.
Lin MH; Li D; Tang B; Li L; Suhrbier A; Harrich D
Microbiol Spectr; 2022 Dec; 10(6):e0394922. PubMed ID: 36445148
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
[TBL] [Abstract][Full Text] [Related]
4. Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy.
Pelz L; Rüdiger D; Dogra T; Alnaji FG; Genzel Y; Brooke CB; Kupke SY; Reichl U
J Virol; 2021 Nov; 95(24):e0117421. PubMed ID: 34550771
[TBL] [Abstract][Full Text] [Related]
5. Generation of "OP7 chimera" defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice.
Dogra T; Pelz L; Boehme JD; Kuechler J; Kershaw O; Marichal-Gallardo P; Baelkner M; Hein MD; Gruber AD; Benndorf D; Genzel Y; Bruder D; Kupke SY; Reichl U
Sci Rep; 2023 Nov; 13(1):20936. PubMed ID: 38017026
[TBL] [Abstract][Full Text] [Related]
6. Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles.
Hein MD; Arora P; Marichal-Gallardo P; Winkler M; Genzel Y; Pöhlmann S; Schughart K; Kupke SY; Reichl U
BMC Biol; 2021 May; 19(1):91. PubMed ID: 33941189
[TBL] [Abstract][Full Text] [Related]
7. Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity.
Bdeir N; Arora P; Gärtner S; Pöhlmann S; Winkler M
Sci Rep; 2021 Oct; 11(1):20477. PubMed ID: 34650149
[TBL] [Abstract][Full Text] [Related]
8. A Novel Type of Influenza A Virus-Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome.
Kupke SY; Riedel D; Frensing T; Zmora P; Reichl U
J Virol; 2019 Feb; 93(4):. PubMed ID: 30463972
[TBL] [Abstract][Full Text] [Related]
9. A system for production of defective interfering particles in the absence of infectious influenza A virus.
Bdeir N; Arora P; Gärtner S; Hoffmann M; Reichl U; Pöhlmann S; Winkler M
PLoS One; 2019; 14(3):e0212757. PubMed ID: 30822349
[TBL] [Abstract][Full Text] [Related]
10. PARP1 Enhances Influenza A Virus Propagation by Facilitating Degradation of Host Type I Interferon Receptor.
Xia C; Wolf JJ; Sun C; Xu M; Studstill CJ; Chen J; Ngo H; Zhu H; Hahm B
J Virol; 2020 Mar; 94(7):. PubMed ID: 31915279
[TBL] [Abstract][Full Text] [Related]
11. Efficient Inhibition of Avian and Seasonal Influenza A Viruses by a Virus-Specific Dicer-Substrate Small Interfering RNA Swarm in Human Monocyte-Derived Macrophages and Dendritic Cells.
Jiang M; Österlund P; Westenius V; Guo D; Poranen MM; Bamford DH; Julkunen I
J Virol; 2019 Feb; 93(4):. PubMed ID: 30463970
[TBL] [Abstract][Full Text] [Related]
12. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target.
Yuan S; Chu H; Huang J; Zhao X; Ye ZW; Lai PM; Wen L; Cai JP; Mo Y; Cao J; Liang R; Poon VK; Sze KH; Zhou J; To KK; Chen Z; Chen H; Jin DY; Chan JF; Yuen KY
Sci Adv; 2020 Aug; 6(35):eaba7910. PubMed ID: 32923629
[TBL] [Abstract][Full Text] [Related]
13. Defective Interfering Particles of Influenza Virus and Their Characteristics, Impacts, and Use in Vaccines and Antiviral Strategies: A Systematic Review.
Wu M; Zhou E; Sheng R; Fu X; Li J; Jiang C; Su W
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560777
[TBL] [Abstract][Full Text] [Related]
14. Production of antiviral "OP7 chimera" defective interfering particles free of infectious virus.
Pelz L; Dogra T; Marichal-Gallardo P; Hein MD; Hemissi G; Kupke SY; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2024 Dec; 108(1):97. PubMed ID: 38229300
[TBL] [Abstract][Full Text] [Related]
15. Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Wang Q; Pan W; Wang S; Pan C; Ning H; Huang S; Chiu SH; Chen JL
J Virol; 2021 Feb; 95(6):. PubMed ID: 33361428
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of JIP4 at S730 Presents Antiviral Properties against Influenza A Virus Infection.
Del Sarto J; Gerlt V; Friedrich ME; Anhlan D; Wixler V; Teixeira MM; Boergeling Y; Ludwig S
J Virol; 2021 Sep; 95(20):e0067221. PubMed ID: 34319782
[TBL] [Abstract][Full Text] [Related]
17. Dengue virus-free defective interfering particles have potent and broad anti-dengue virus activity.
Li D; Lin MH; Rawle DJ; Jin H; Wu Z; Wang L; Lor M; Hussain M; Aaskov J; Harrich D
Commun Biol; 2021 May; 4(1):557. PubMed ID: 33976375
[TBL] [Abstract][Full Text] [Related]
18. Indole alkaloids inhibit zika and chikungunya virus infection in different cell lines.
Monsalve-Escudero LM; Loaiza-Cano V; Pájaro-González Y; Oliveros-Díaz AF; Diaz-Castillo F; Quiñones W; Robledo S; Martinez-Gutierrez M
BMC Complement Med Ther; 2021 Aug; 21(1):216. PubMed ID: 34454481
[TBL] [Abstract][Full Text] [Related]
19. Defective Influenza A Virus RNA Products Mediate MAVS-Dependent Upregulation of Human Leukocyte Antigen Class I Proteins.
Rahim MMA; Parsons BD; Price EL; Slaine PD; Chilvers BL; Seaton GS; Wight A; Medina-Luna D; Dey S; Grandy SL; Anderson LE; Zamorano Cuervo N; Grandvaux N; Gaglia MM; Kelvin AA; Khaperskyy DA; McCormick C; Makrigiannis AP
J Virol; 2020 Jun; 94(13):. PubMed ID: 32321802
[TBL] [Abstract][Full Text] [Related]
20. Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons.
Czerkies M; Kochańczyk M; Korwek Z; Prus W; Lipniacki T
J Virol; 2022 Nov; 96(22):e0134122. PubMed ID: 36326278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
